Seventure Partners, a Paris, France-based life science microbiome investment firm, completed the first closing of its second dedicated fund.
Backers included returing investors such as Danone, Novartis, Lesaffre, Tornier, Unigrains and Bel, as well as new strategic industry partners including a US based global food ingredient provider (to be disclosed), alongside financial institutional Limited Partners and entrepreneurial investors.
The fundraising was led by Isabelle de Cremoux, CEO and Managing Partner of Seventure Partners.
With a target for the final close of over €200m, Health for Life Capital II has a “beyond the pill” investment strategy, keeping its core focus on the microbiome, including platforms, drugs, nutritional solutions, diagnostics and biomarkers, as well as opportunistic investments in digital therapeutics, connected health, digital nutritional advice, personalised nutrition, precision medicine and food technologies.
HFL II will seek to invest in a approx. 20 companies, with a global focus, spanning Europe, North America, Israel, and opportunistically Asia.
Investments can range between €500k and €10m per round, or up to €20m per company, from early to late stage.
The fund has already committed money to:
– Axial Biotherapeutics in the US, and
– Galecto Biotech in Denmark.
The first €160m Health for Life Capital™ fund – launched in 2014 – has invested in 20 companies at the forefront of their fields, such as Enterome, Vedanta Biosciences, MaaT Pharma, Eligo Bioscience, LNC Therapeutics, TargEDys, A-Mansia Biotech, BiomX, Microbiotica, Anaeropharma, NeurIMM, Siolta Therapeutics, DayTwo, Zipongo, Mdoloris Medical Systems, MycoTechnology, etc. It achieved its first transactional exit with the trade sale of Cambrooke in 2017.
In March 2018, the firm also launched AVF, a new fund dedicated to innovative solutions for animal nutrition, feed and health.